Search

everythinglearnresearchcommunity

for

Search:↓

User asks about Pyrilutamide release in Europe, specifically Germany, and considers importing it from China. No specific treatments mentioned.

The post and conversation are about a user claiming to be 137 years old with a full head of hair. Specific treatments mentioned include dutasteride, RU58841, and minoxidil.

The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

The conversation is about a user's hair loss treatment routine, which includes RU58841 for 9 months and Dutasteride for 6 months, with other unspecified treatments considered extra. One user inquired about the source of RU58841.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The conversation discusses using finasteride, dutasteride, RU58841, and testosterone to combat hair loss and block DHT, with some users expressing concerns about side effects and vegan options for medication. The discussion also touches on personal experiences with hormone treatments and the desire to maintain a youthful appearance.

The user has been using Pyrilutamide (Pyril) for hair loss for a month alongside finasteride/dutasteride since 2021 but hasn't seen results. They are considering switching to RU58841 due to its many success stories, despite being skeptical about the legitimacy and testing of Pyrilutamide.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

The conversation discusses the storage and use of pyrilutamide for hair loss, where one user advises against keeping it in the freezer as it may crystallize the active compounds.

The conversation is about updates on hair loss treatments Breezula or PTD-DBM. No new information was provided.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.

A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.